Prion disease is a group of rare, fatal brain disorders caused not by a virus or bacterium, but by a misfolded protein that triggers a chain reaction of destruction in the nervous system. These diseases affect roughly 1 to 2 people per million worldwide each year, and they remain among the most feared diagnoses in neurology because there is currently no cure. Understanding what prion disease is, how it works, and what forms it takes can help make sense of a condition that sits at the intersection of infectious disease, genetics, and neurodegeneration.
How a Single Misfolded Protein Damages the Brain
Your body naturally produces a protein called prion protein, which sits on the surface of nerve cells. Scientists still don’t fully understand its normal function, but the protein is harmless in its usual shape. Prion disease begins when this protein refolds into an abnormal configuration. The misfolded version is insoluble, resistant to the body’s normal cleanup processes, and, critically, it acts as a template: when it contacts a normally shaped prion protein, it forces that protein to misfold too.
This creates a self-perpetuating chain reaction. One misfolded protein converts another, which converts another, and so on. The abnormal proteins clump together into sticky fibers called amyloid fibrils that accumulate in brain tissue. Over time, neurons die and the brain develops a distinctive sponge-like appearance, riddled with tiny holes (vacuoles) visible under a microscope. This “spongiform change” is the signature of prion disease and the reason these conditions are formally called transmissible spongiform encephalopathies. Alongside the holes, the brain shows widespread inflammation, loss of synaptic connections between neurons, and scarring by support cells called astrocytes.
The Three Ways Prion Disease Begins
Human prion diseases fall into three categories based on how the initial misfolding event starts.
Sporadic (about 85% of cases): The misfolding appears to happen spontaneously, without any known trigger. Sporadic Creutzfeldt-Jakob disease (CJD) is by far the most common form. Less common sporadic types include sporadic fatal insomnia and a condition called variably protease-sensitive prionopathy. Most sporadic CJD patients are between 60 and 70 years old.
Genetic (10 to 15% of cases): Mutations in the PRNP gene, which provides the blueprint for prion protein, make the protein more likely to misfold. Some mutations swap a single building block in the protein’s chain; others insert extra segments or produce a shortened version. These inherited mutations cause genetic CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI). A parent with one of these mutations has a 50% chance of passing it to each child.
Acquired (about 1% of cases): Prion disease can be transmitted from an external source. The most well-known example is variant CJD (vCJD), linked to eating beef from cattle infected with bovine spongiform encephalopathy, commonly called “mad cow disease.” Feeding cattle meat and bone meal from other dead cows, some of which carried the disease, fueled a large outbreak in the United Kingdom starting in the mid-1980s. Other acquired forms include kuru, historically spread through ritualistic cannibalism in Papua New Guinea, and iatrogenic CJD, transmitted through medical procedures. More than 500 iatrogenic cases have been documented, mostly linked to contaminated human growth hormone derived from cadavers and transplanted tissue from the brain’s outer covering. Contaminated corneal transplants and neurosurgical instruments have also been implicated, though improved decontamination procedures introduced in the 1970s largely eliminated that risk.
Symptoms and How Quickly It Progresses
The specific symptoms depend on the type of prion disease, but most forms share a core pattern of rapid cognitive decline, movement problems, and behavioral changes. Early signs of CJD, the most common form, often include poor coordination, trouble walking, confusion, and difficulty with memory and judgment. Many patients also experience depression, mood swings, anxiety, vision changes, insomnia, tremor, and hallucinations. As the disease progresses, involuntary muscle jerks (called myoclonus) become prominent, and patients develop severe dementia.
The speed of decline is one of the most striking features. About 70% of people with CJD die within one year of their first symptoms. Variant CJD is somewhat different: it tends to strike younger people, sometimes in their teens, and typically begins with psychiatric symptoms like depression and anxiety before neurological signs appear. It also progresses more slowly than sporadic CJD, though the outcome is the same. GSS, on the other hand, often starts with slowly worsening coordination problems and may take several years before dementia develops.
How Prion Disease Is Diagnosed
Diagnosing prion disease has historically been difficult because many of its symptoms overlap with other forms of dementia, and a definitive answer once required examining brain tissue after death. That has changed significantly with the development of a spinal fluid test called RT-QuIC (real-time quaking-induced conversion). This test works by seeing whether a patient’s spinal fluid can trigger the characteristic misfolding chain reaction in a lab setting. In a large prospective study of patients with suspected sporadic CJD, RT-QuIC achieved 96% sensitivity and 100% specificity, meaning it catches nearly all true cases while producing virtually no false positives. That is a dramatic improvement over older spinal fluid markers, which had specificity as low as 46%.
Brain MRI also plays an important role. Certain patterns of signal abnormality on MRI scans are highly suggestive of CJD, and when combined with RT-QuIC results and clinical presentation, doctors can now reach a confident diagnosis during a patient’s lifetime. For genetic forms, testing for mutations in the PRNP gene can confirm the diagnosis and identify at-risk family members before symptoms appear.
What the Brain Looks Like in Different Forms
Although all prion diseases damage the brain, the specific pattern varies by type, which is part of how pathologists distinguish between them. The most common subtype of sporadic CJD produces small vacuoles scattered throughout the brain along with a fine, “synaptic” pattern of abnormal protein deposits. Other subtypes create large, merging vacuoles or concentrate damage in deep layers of the cortex. About 10% of sporadic CJD cases show distinct amyloid plaques in the brain.
Variant CJD has its own hallmark: “florid plaques,” which look like a dense core of amyloid protein surrounded by a halo of radiating fibers and a ring of vacuoles. These plaques are widespread throughout the brain. GSS, in contrast, is defined by abundant amyloid plaques in the cerebral and cerebellar cortex, sometimes with little or no spongiform change at all. These distinctions matter because they help confirm a diagnosis and can provide clues about the underlying molecular strain of the disease.
Treatment and Experimental Approaches
There is no approved treatment that slows, stops, or reverses any form of prion disease. Current medical care focuses entirely on managing symptoms and keeping patients as comfortable as possible.
One of the most promising experimental approaches targets the problem at its root: rather than trying to clear misfolded proteins after they form, it aims to reduce the amount of normal prion protein available to be converted. Researchers Sonia Vallabh and Eric Minikel, both of whom carry a genetic prion mutation, collaborated with the biotech company Ionis Pharmaceuticals to develop a drug called ION717. It uses a technology called antisense oligonucleotides, short strands of synthetic genetic material that bind to the messenger RNA for prion protein and prevent the cell from producing it. If the brain makes less prion protein overall, there is less raw material for the misfolding chain reaction to exploit. An early-stage clinical trial of ION717 was fully enrolled as of December 2024, and results will help determine whether lowering prion protein levels in humans is safe and effective.
This strategy represents a fundamental shift. Instead of targeting the disease after it has taken hold, it could potentially be used preventively in people who carry genetic mutations but haven’t yet developed symptoms.